Cantor Fitzgerald analyst Rick Bienkowski initiated coverage of Verve Therapeutics with a Neutral rating and $21 price target. The development of gene-editing medicines for a mass market indication carries heightened clinical and commercial risk compared to other gene editing programs, and Cantor Fitzgerald believes the FDA has shown scrutiny in initiating in vivo gene-editing clinical trials in the U.S., the analyst tells investors in a research note. The firm expects the degree of scrutiny to increase as clinical studies transition from the high-risk heterozygous familial hypercholesterolemia patients to broader patient populations.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VERV:
- Sell these stocks now, proven algorithm says
- Short Report: Bears pounce on disappointing drug news from Gossamer and Verve
- Verve Therapeutics initiated with a Sell at Goldman Sachs
- Verve Plunges After FDA Clinical Hold
- Verve FDA request ‘provides fodder for both bulls and bears,’ says Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue